[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-04-29
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has extended the confidentiality withholding deadline for disclosing its counterparty regarding a KRW 107.5B letter of intent (LOI) for a biopharmaceutical contract manufacturing agreement to May 31, 2024, following consultations with the client. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key…